AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00820027
Drug: Matching Placebo for Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet three times daily
Trial: NCT02796820
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Trial: NCT03821610
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT04255069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Trial: NCT04255069
Drug: Dose 1 JKB-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Trial: NCT04255069
Drug: Dose 2 JKB-122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Trial: NCT04311619
Drug: [11C]UCB-J radiotracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
Trial: NCT01500668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
Trial: NCT01266135
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAX576 10 mg/kg intravenous infusion
Trial: NCT01266135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QAX576 intravenous infusion
Trial: NCT00336414
Drug: cyclophosphamide-prednisone-azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01534195
Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop in each eye, four times/day for 8 days.
Trial: NCT01534195
Drug: Tears Naturale II Ophthalmic Solution
RxNorm normalized name: Tears Naturale Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in each eye, four times/ day (QID) for 8 days
Trial: NCT02356289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00272610
Drug: 0.4% Retinol Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00635882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F MDI placebo twice daily (BID) (2 inhalations)
Trial: NCT01340573
Drug: PegIntron Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
Trial: NCT00403728
Drug: ciclosporine A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
Trial: NCT02182570
Drug: WAL 801 CL dry syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02302404
Drug: GSK2982772 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Trial: NCT02302404
Drug: GSK2982772 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
Trial: NCT02302404
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Trial: NCT04325620
Drug: HIP1601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIP1601
Trial: NCT04325620
Drug: HGP1805
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of HIP1601
Trial: NCT01998308
Drug: Crespine gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Knees will have single injection of Crespine gel
Trial: NCT03888820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Trial: NCT01998308
Drug: Intragel
RxNorm normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL LOTION [INTRAL SENSITIVE SKIN ENVIRONMENTAL LIGHTWEIGHT SHIELD BROAD SPECTRUM SPF50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Knees will have single injection of 2 ampules of Intragel
Trial: NCT01998308
Drug: Crespine plus gel
RxNorm normalized name: Quest Plus Oral Gel Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 Knees will have single injection of Crespine Plus Gel
Trial: NCT02302404
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size 00 White Opaque capsule containing Placebo as white to almost white solid
Trial: NCT02498496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 100 mL of Normal Saline
Trial: NCT00956462
Drug: Ketorolac (NSAID) versus Dexamethasone (steroid)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device
Trial: NCT02629289
Drug: US-approved Neulasta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02629289
Drug: EU-approved Neulasta
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00176462
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Trial: NCT00176462
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Trial: NCT00176462
Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00176462
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01453608
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo (saline) intravenously on Day 0
Trial: NCT00010881
Drug: antioxidants
RxNorm normalized name: E Complex with Antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00863291
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in a manner similar to the active comparator
Trial: NCT01714401
Drug: Salbutamol 2,5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 min nebulization of 2.5 mg of salbutamol
Trial: NCT00196872
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is given
Trial: NCT00196872
Drug: Ibandronat
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronat is given
Trial: NCT01809184
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo adminstered corresponding to insulin 287 treatment
Trial: NCT02335125
Drug: Psychotropic Drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01937325
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active arm
Trial: NCT00147355
Drug: ondansetron, ibuprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Trial: NCT00147355
Drug: Ondansetron, ibuprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Trial: NCT00147355
Drug: metoclopramide, ibuprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Trial: NCT00147355
Drug: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Trial: NCT00652860
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02042196
Drug: Placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive transdermal patch
Trial: NCT03875690
Drug: Injection of methylprednisolone
RxNorm normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
Trial: NCT00604864
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03442218
Drug: Clorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
Trial: NCT00246701
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin
Trial: NCT00246701
Drug: Simvastatin + Lovaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin + Lovaza (omega-3-acid ethyl esters)
Trial: NCT00279773
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01862640
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, tablets
Trial: NCT01384422
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01854437
Drug: Mg Oxide
RxNorm normalized name: citric acid/Mg oxide/Na picosulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg orally for 4 weeks
Trial: NCT02391181
Drug: Iron Sucrose Azad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Trial: NCT03936829
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
Trial: NCT01101165
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 40-mg tablet x 1 dose taken without food
Trial: NCT01101165
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
Trial: NCT02391181
Drug: Venofer®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
Trial: NCT00372970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline injection into pylorus.
Trial: NCT00601640
Drug: Diclofenac Na gel
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given topically twice daily on days 1-90
Trial: NCT02720692
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00508885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00462189
Drug: Immunotoxin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02544282
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Pecs II block
Trial: NCT02544282
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: General Anesthesia
Trial: NCT04607525
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the scheduled time of operation, the head nurse opened each envelope just before surgery, prepared the infusion solution and handled it to the anesthesiologist who was blinded to the solution. He was then determined for collecting perioperative data.~Group C: Patients received equal volume and rate of normal saline as Group D.
Trial: NCT00258791
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00852228
Drug: HAI chronomodulated chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks.
Trial: NCT00852228
Drug: HAI conventional chemotherapy
RxNorm normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks.
Trial: NCT00335556
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00335556
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03321734
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
Trial: NCT03321734
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
Trial: NCT04609059
Drug: M201-A Injection
RxNorm normalized name: OCTINOXATE 2.45 g in 35 g / TITANIUM DIOXIDE 4.03 g in 35 g / ZINC OXIDE 1.72 g in 35 g / OCTISALATE 1.58 g in 35 g TOPICAL CREAM [15HR COVER LASTING M201 Medium Beige SPF50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: M201-A Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Trial: NCT04609059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Placebo: M201-A Placebo Route of administration: continuous intravenous injection~Step 1: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.4 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes Step 2: Continuous Intravenous Injection administered with single dose of M201-A hydrochloride or placebo 0.6 mg/kg in 50 mL, controlled with a syringe driver at a rate of 2.5 mL/min for 20 minutes (Based on recommendations of an independent data monitoring committee; data and safety monitoring board, it will be decided that dosage is 0.20 mg/kg or 0.40 mg/kg. If appropriate, Step 2 will not be conducted.)
Trial: NCT00331214
Drug: Testosterone Transdermal System
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone patch (300 mcg/day), patch changed twice a week for six months
Trial: NCT00331214
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch replaced every 3-4 days for 6 months
Trial: NCT02757404
Drug: Manual needle placement injection of Meditoxin®.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
Trial: NCT00916006
Drug: PEP005 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015%, three day treatment
Trial: NCT00916006
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel, three day treatment
Trial: NCT02005666
Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Trial: NCT02005666
Drug: DUAC® Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Trial: NCT00791089
Drug: LOVAZA Omega 3-acid ethyl esters
RxNorm normalized name: omega-3 acid ethyl esters (USP) 1000 MG [Lovaza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
Trial: NCT03986528
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle) according pathologic types. Patients with CR, PR, or SD after 4-6 cycles of platinum-based double chemotherapy regimens will receive non-platinum single-agent chemotherapy.
Trial: NCT00668811
Drug: SU011248, Sutent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
Trial: NCT00244101
Drug: PS Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
Trial: NCT00244101
Drug: ISX Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
Trial: NCT01605136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo subcutaneous implant every 2 months for 6 months